News Releases
In this section
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 27, 2003Insmed Incorporated Appeals Delisting Notification From Nasdaq
RICHMOND, Va.--(BUSINESS WIRE)--Jan. 27, 2003--Insmed Incorporated (NASDAQ:INSM) announced today that it has requested a hearing before a Nasdaq Listing Qualifications Panel to appeal an earlier...
-
Jan 7, 2003Insmed Incorporated Announces Positive Preclinical Oncology Data With rhIGFBP-3
RICHMOND, Va.--(BUSINESS WIRE)--Jan. 7, 2003--Insmed Incorporated (Nasdaq:INSM) reported today that recombinant human IGFBP-3 (rhIGFBP-3) has demonstrated significant decrease in cell...
-
Dec 16, 2002Insmed Announces Senior Management Changes
RICHMOND, Va.--(BUSINESS WIRE)--Dec. 16, 2002--Insmed Incorporated (Nasdaq: INSM) announced today the resignation of Fredrick L. Dunn, M.D. and Mary Callan, Ph.D. as vice president of clinical...
-
Nov 4, 2002Insmed Presents IGFBP-3 Anti-Cancer Data at the International Symposium on the Functional Role of IGFBP's
RICHMOND, Va., Nov 4, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) today announced that data was presented on its preclinical anti-tumor biotherapeutic, insulin-like growth factor...
-
Oct 31, 2002Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT
CTRICHMOND, Va., Oct 24, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) will announce financial results for the third quarter of 2002 at approximately 4:00 p.m. EST on Wednesday,...
-
Oct 30, 2002Insmed Incorporated Reports Third Quarter Results
RICHMOND, Va., Oct 30, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) today announced financial results for the three- and nine-month periods ended September 30, 2002. Revenues for the...
-
Oct 7, 2002Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine
RICHMOND, Va., Oct 7, 2002 (BUSINESS WIRE) -- Insmed to Continue Pharmacia's Treatment Program for Children With GHIS Insmed Incorporated (Nasdaq: INSM) announced today that Pharmacia Corporation...
-
Sep 23, 2002Insmed Restructures to Advance Most Promising Drug Candidates and Optimize Resources
RICHMOND, Va., Sep 23, 2002 (BUSINESS WIRE) -- Company to Focus on Development and Commercialization Of SomatoKine® and IND Preparation for New Clinical Candidate, IGFBP-3 Insmed Incorporated...
-
Sep 10, 2002Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -
RICHMOND, Va., Sep 10, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM): Decision Follows Results of Phase II Clinical Trials Company Will Direct Resources Toward Most Promising Clinical...
-
Sep 9, 2002Insmed Announces Appointment of Mary Callan as Vice President of Corporate Development
RICHMOND, Va., Sep 9, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) today announced the appointment of Mary Callan, Ph.D as Vice President of Corporate Development. Dr. Callan joins...
Contact Us
